Astria Therapeutics, Inc. (ATXS)

Market Cap	215.35M
Revenue (ttm)	n/a
Net Income (ttm)	-49.01M
Shares Out	28.04M
EPS (ttm)	-2.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	161,550
Open	6.88
Previous Close	6.99
Day's Range	6.87 - 7.72
52-Week Range	6.73 - 16.28
Beta	0.86
Analysts	Strong Buy
Price Target	23.25 (+202.73%)
Earnings Date	Nov 9, 2023

About ATXS

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 25, 2015
• Employees: 45
• Stock Exchange: NASDAQ
• Ticker Symbol: ATXS

Analyst Forecast

According to 4 analysts, the average rating for ATXS stock is "Strong Buy." The 12-month stock price forecast is $23.25, which is an increase of 202.73% from the latest price.

Price Target

$23.25

(202.73% upside)

Analyst Consensus: Strong Buy